Resumen
Compounds of formula (I), wherein X is selected from the group consisting of O, and NR<3>, where R<3> represents a lower alkyl group; Y is selected from the group consisting of CH and N; R<1> and R<2> are independently selected from the group consisting of NH2, NHR<4> and NR<5>2, where R<4> and R<5> each represent a lower alkyl group, or R<1> and R<2> together represent a cycle selected from (a), (b) and (c), wherein R<6>, R<7> and R<8> are independently selected from the group consisting of hydrogen atoms, lower alkyl groups, hydroxy groups and lower alkoxy groups; and Z is selected from the group consisting of O.
Reivindicaciones
Claims 1. 1. A compound of formula (I): N R1 Y R2 X (I) wherein: X is selected from the group consisting of 0, and NR3, where R3 represents a lower alkyl group; Y is selected from the group consisting of CH and N; R1 and R2 are independently selected from the group consisting of NH2, NHR4 and NR25, where R4 and R5 each represent a lower alkyl group, or R1 and R2 together represent a cycle selected from (a), (b) and (c): R6 R6 N R8 (a) R7 (b) R7 (c) R7 Z O N R8 R6 wherein R6, R7 and R8 are independently selected from the group consisting of hydrogen atoms, lower alkyl groups, hydroxy groups and lower alkoxy groups; and Z is selected from the group consisting of 0 and NH; and pharmaceutically acceptable salts thereof. A compound according to Claim 1, wherein X represent an oxygen atom. SUBSTITUTE SHEET (RULE 26) 4. A compound according to any one of Claims 1 to 3, wherein R and R2 together represent a cycle of formula (a). 5. A compound according to any one of Claims 1 to 3, wherein R1 and R2 together represent a cycle of formula (b). 6. A compound according to any one of Claims 1 to 3, wherein R1 and R2 together represent a cycle of formula (c). 7. A compound according to Claim 4, wherein R6 and R7 are independently selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms, hydroxy groups and alkoxy groups having from 1 to 4 carbon atoms. 8. A compound according to Claim 7, wherein R6 and R7 are independently selected from the group consisting of hydrogen atoms, methyl groups and ethyl groups. 9. A compound according to Claim 8, wherein R6 represents a methyl group and R7 represents a hydrogen atom. 10. A compound according to any one of Claims 4 and 7 to 10, wherein Z represents a group of formula NH. 11. A compound according to Claim 6, wherein R6, R7 and R8 are selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms, hydroxy groups and alkoxy groups having from 1 to 4 carbon atoms. 12. A compound according to Claim 11, wherein R6, R7 and R8 are independently selected from the group consisting of hydrogen atoms, methyl groups, ethyl groups and hydroxy groups. 13. A compound according to Claim 12, wherein R6 represents a hydroxy group and R7 and R8 each represent a hydrogen atom. 14. A compound according to Claim 1 having the following formula (II): N R6 R7 N N O H (11) wherein R6 and R7 are as defined in Claim 1. 15. A compound according to Claim 14, wherein R6 represents a methyl group and R7 represents a hydrogen atom. 16. A compound according to Claim 1 having the following formula (III): N N R8 N R7 o OH (III) wherein R7 and R8 are as defined in Claim 1. 17. A compound according to Claim 16, wherein R7 and R8 each represent a hydrogen atom. 18. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of Claim 1 to 17 in admixture with a pharmaceutically acceptable carrier or diluent. 19. A pharmaceutical composition according to Claim 18 having antitumor activity. 20. A pharmaceutical composition according to Claim 19, for the treatment of malignant tumors. 21. A compound of formula (I) according to any one of Claims 1 to 17 for use in therapy. 22. Use of a compound of formula (I) according to any one of Claims 1 to 17 in the manufacture of a medicament for the treatment of malignant tumors. 23. A method for treating a mammal affected by a maligant tumor, comprising the administration to the affected individual of an effective amount of a compound of formula (I) according to any one of Claims 1 to 17. 24. 24. A process for the proiduction of compounds of formula (II), as defined in Claim 14, comprising: (a) reaction of a compound of formula 1b: F3COCHN N NMe2 1b with a compound of formula 6: O R6 R7 N O O H 6 wherein R6 and R7 are as defined in Claim 1, to give a compound of formula 7: wherein R6 and R7 are as defined in Claim 1; (b) aromatization of the compound of formula 7 in the presence of a Pd-C catalyst, to give a compound of formula 9: F3COCHN O R6 R7 N N O O H 9 wherein R6 and R7 are as defined in Claim 1; and (iii) hydrolytic cyclization of the compound of formula 9 to give the compound of formula (II). 25. A process for the production of a compound of formula (III), as defined in Claim 16, comprising: (a) reaction of a compound of formula la: O2N N NMe2 la SUBSTITUTE SHEET (RULE 26) wherein R7 and R8 are as defined in Claim 1, to give a compound of formula 12: O2N O N R8 N R7 O C1 12 wherein R7 and R8 are as defined in Claim 1; and (b) hydrogenation of the compound of formula 12 in the presence of a Pd-C catalyst followed by acidic hydrolytic work-up, to give the compound of formula (III).
